Business
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues increased 5% YoY in LC.Key Innovative brands continued to drive growth and provide value for patients, with 2025 revenues surpassing $3 billion, +35% YoY in LC: AUSTEDO® global revenues of $2.26 billion, growing 34% YoY in LC. AJOVY® global revenues of $673 million, up 30% YoY in LC
About this update from Teva Pharmaceutical Industries Limited
[{"type":"image","alt":"Teva Pharmaceutical Industries Ltd","displaySize":"","headline":null,"caption":"Teva Pharmaceutical Industries Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/bfbffad044ba3112cbe08e7be13bb2e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vrlzyJKRPwSh_YtGafCgLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bfbffad044ba3112cbe08e7be13bb2e7","width":300,"height":108}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues increased 5% YoY in LC.","length":240,"tagName":"p"}]},{"val":[{"type":"text","content":"Key Innovative brands continued to drive growth and provide value for patients, with 2025 revenues surpassing $3 billion, +35% YoY in LC:","length":137,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"AUSTEDO® global revenues of $2.26 billion, growing 34% YoY in LC.","length":65,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":65,"olType":false}]}],"tagName":"ul","bulletedList":true,"length":442,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"AJOVY® global revenues of $673 million, up 30% YoY in LC.","length":57,"tagName":"p"}]},{"val":[{"type":"text","content":"UZEDY® revenues of $191 million, up 63% YoY in LC; underscoring Teva's commitment to drive new advances in neuroscience:","length":124,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Fastest growing long-acting injectable (LAI)1","length":45,"tagName":"p"}]},{"val":[{"type":"text","content":"FDA expanded indication approval for Bipolar 1 Disorder.","length":56,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":101,"olType":false}]},{"val":[{"type":"text","content":"Q4 2025 marks the first quarter in which these key brands collectively delivered ~$1 billion of revenues.","length":105,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":387,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Generics portfolio stable:","length":26,"tagName":"p"},{"type":"list",...